NCT05227937 · ClinicalTrials.gov record · last posted 2026-03-04
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
StatusRecruiting
PhaseNot specified
Started2022-09-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 4, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.
Amendment record
9 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 9 times since 2022-01-27; most recent amendment 2026-03-02. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2022-09-22
Status change Not Yet Recruiting→Recruitingv4
| NCT Number |
NCT05227937 |
| Lead Sponsor |
Antonios Likourezos
|
| Conditions |
Urinary Tract Infections |
| Enrollment |
75 participants |
| Start Date |
2022-09-21 |
| Primary Completion |
2026-05-31 (estimated) |
| Study Completion |
2026-12-31 (estimated) |
| Updated on ClinicalTrials.gov |
2026-03-04 |